Search research articles
Contact Us
Filters
Showing results (1-10 of 224) with videos related to
Page
of 23
Sort By:
The Lancet. Oncology
|
January 6, 2018
Dacomitinib in NSCLC: a positive trial with little clinical impact
Alfredo Addeo
Frontiers in Oncology
|
December 19, 2022
Editorial: Insights in thoracic oncology: 2021/2022
Kaushal Parikh, Alfredo Addeo
International Journal of Cancer
|
May 11, 2018
Negative phase 3 randomized controlled trials: Why cancer drugs fail the last barrier?
Bishal Gyawali, Alfredo Addeo
Revue Medicale Suisse
|
May 19, 2021
[Non-small cell lung cancer: a target biology]
Nathalie Baudoux, Alfredo Addeo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2015
Optimal Concurrent Chemoradiotherapy Regimen in Non-Small-Cell Lung Cancer: Prospective, Randomized Data Still Required
Alfredo Addeo, Charles Comins
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2024
Shrinking sample sizes in lung cancer trials: Various explanations, open questions
Timothée Olivier, Alfredo Addeo
The Lancet. Oncology
|
May 3, 2019
SABR versus conventional fractionation regimens in NSCLC
Alfredo Addeo, Lucio Buffoni
Drugs in Context
|
July 20, 2018
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
Alfredo Addeo, Giulio Metro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
Alfredo Addeo, Amit Bahl
Case Reports in Oncology
|
December 7, 2016
Intrathecal Methotrexate and Craniospinal Radiotherapy Can Be an Effective Treatment of Carcinomatous Meningitis in Patients with Breast Cancer: Case Reports
Magdalena Meissner, Alfredo Addeo
Page
of 23
Search research articles
Search
Showing results (1-10 of 224) with videos related to
Sort By:
Page
of 23
The Lancet. Oncology
|
January 6, 2018
Dacomitinib in NSCLC: a positive trial with little clinical impact
Alfredo Addeo
Frontiers in Oncology
|
December 19, 2022
Editorial: Insights in thoracic oncology: 2021/2022
Kaushal Parikh, Alfredo Addeo
International Journal of Cancer
|
May 11, 2018
Negative phase 3 randomized controlled trials: Why cancer drugs fail the last barrier?
Bishal Gyawali, Alfredo Addeo
Revue Medicale Suisse
|
May 19, 2021
[Non-small cell lung cancer: a target biology]
Nathalie Baudoux, Alfredo Addeo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2015
Optimal Concurrent Chemoradiotherapy Regimen in Non-Small-Cell Lung Cancer: Prospective, Randomized Data Still Required
Alfredo Addeo, Charles Comins
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2024
Shrinking sample sizes in lung cancer trials: Various explanations, open questions
Timothée Olivier, Alfredo Addeo
The Lancet. Oncology
|
May 3, 2019
SABR versus conventional fractionation regimens in NSCLC
Alfredo Addeo, Lucio Buffoni
Drugs in Context
|
July 20, 2018
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
Alfredo Addeo, Giulio Metro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
Alfredo Addeo, Amit Bahl
Case Reports in Oncology
|
December 7, 2016
Intrathecal Methotrexate and Craniospinal Radiotherapy Can Be an Effective Treatment of Carcinomatous Meningitis in Patients with Breast Cancer: Case Reports
Magdalena Meissner, Alfredo Addeo
Page
of 23